Q-omics provides the consensus-scored ATXN1L profile across patient tissues and cancer cell-line models. ATXN1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATXN1L is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ATXN1L RNA expression shows 20,479 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ATXN1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATXN1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATXN1L survival associations across molecular data types. ATXN1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATXN1L RNA expression–survival associations across cancer types. High ATXN1L expression shows unfavorable associations in BLCA and LGG, but favorable associations in KIRC, HNSC, SCLC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATXN1L RNA expression.
This table summarizes ATXN1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ATXN1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATXN1L shows lower tumor expression in KICH, THCA, LUAD and BRCA and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher ATXN1L RNA expression in normal versus tumor tissue (log2 FC = −1.434, t-test p < 0.001).
This table shows molecular features associated with ATXN1L in patient tissues and cancer cell lines. In patient samples, ATXN1L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATXN1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
